Hormonal
GLP-1 receptor agonists (semaglutide, tirzepatide) are effective for weight loss in the general population but demonstrate attenuated efficacy and unclear safety profiles specifically in breast cancer patients, particularly those receiving endocrine therapy.
If you have breast cancer and are taking hormonal therapy (like aromatase inhibitors), GLP-1 drugs like Semaglutide or Tirzepatide will likely help you lose weight, but not as much as they do for people without cancer. You should expect roughly half the weight loss seen in the general population. Discuss this with your oncologist, as safety data in your specific group is still being gathered.
When compared to weight reductions of −14% with semaglutide, −8.4% with liraglutide, −10% with dulaglutide and −15% with tirzepatide in the general population, the authors concluded that the impact of GLP-1 agonists may be attenuated in women with breast cancer receiving endocrine therapy [89].
Why this rating
Based on retrospective cohort studies and small case series; large randomized controlled trials (RCTs) explicitly excluded breast cancer patients.
Source
The Impact and Safety of GLP‐1 Agents and Breast Cancer
Kayla Parsons et al. · Cancer Medicine · 2025
DOI 10.1002/cam4.70932
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →